Navigation Links
UT Southwestern testing new hybrid hearing device combining advantages of hearing aids, implants
Date:4/17/2008

DALLAS April 17, 2008 A new hybrid hearing aid/cochlear implant device designed for patients who can benefit from both is being evaluated by UT Southwestern Medical Center otolaryngologists, as part of a multisite, national study.

The cross-breed device, called the DUET Electric-Acoustic System, or EAS, is already used in Europe, but not yet approved for use in the U.S. It targets a population currently falling through the cracks borderline cases for which hearing aids dont adequately distinguish sounds, but for who some natural hearing remains. For these individuals, cochlear implants that entirely replace natural hearing arent recommended either.

Hearing aids are typically worn on the outside of the ear by people who still have some natural hearing. Cochlear implants are surgically implanted into the ear and pick up lost middle- and higher-frequency sounds. They replace lost natural hearing by digitizing electrical impulses sent to the brain via wires implanted in the ear. The brain then interprets that as sound.

Most people with hearing difficulties have one or the other device, but not both.

Initial studies on the hybrid device suggest there is a synergistic effect achieved by maintaining the natural hearing and coupling it with the cochlear implant, particularly for distinguishing speech in noisy environments. The device both amplifies low frequencies and electronically stimulates middle and high frequencies.

The implant is specifically designed with a thin electrode to occupy less space in the inner ear. It is implanted by special surgical techniques to preserve natural hearing.

What patients can hope to get from the investigational device is a significant improvement in the ability to understand speech, especially in a noisy situation, said Dr. Peter Roland, chairman of otolaryngology-head and neck surgery at UT Southwestern.

The device is made by MED-EL Corp., which c
'/>"/>

Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

0

GOOD

Page: 1 2

Related medicine news :

1. UT Southwestern researchers investigate predictors for sickle-cell-anemia complications
2. UT Southwestern surgeons complete North Texas first single-incision gallbladder removal
3. UT Southwestern plastic surgeons deploy new carbon dioxide-based fractional laser
4. BMI criteria for obesity surgery should be lowered, UT Southwestern researchers suggest
5. UT Southwestern: Patients with mild Cushing syndrome may benefit from adrenalectomy
6. Physicians seek to improve the quality of sleep in ICU, researchers at UT Southwestern report
7. UT Southwestern urologist uses Botox to treat debilitating condition
8. UT Southwestern researcher named Howard Hughes Medical Institute investigator
9. 2 UT Southwestern researchers elected to National Academy of Sciences Institute of Medicine
10. UT Southwestern investigating hypothermic technique in treating pediatric head injuries
11. UT Southwestern scientist receives NIH Directors New Innovator Award
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UT Southwestern testing new hybrid hearing device combining advantages of hearing aids, implants
UT Southwestern testing new hybrid hearing device combining advantages of hearing aids, implants
(Date:10/10/2008)...n (a) levels boost cardiovascular disease risk fo...y News) -- If you,re worried about reducing your r...at you should quit smoking, eat a healthful diet, ...eck, and make sure your cholesterol levels aren,t ...ein (a) levels are? , Well, if you don,t have ...
(Date:10/10/2008)...mpany committed to helping people address health n.../ -- In these troubling,economic times, people may... may feel that they don,t have the money to visit ...a survey by the National Association of,Insurance ... -- Twenty-two percent of Americans say that they ...
(Date:10/10/2008)...Oct. 10 /PRNewswire/ -- Do you think that the blin...d town? Attend the October,17 open house at the Vi...ion Impaired, and see how instructors there empowe...ve, fulfilling lives through non-visual,techniques...1 Azalea Avenue, is holding an open house to,celeb...
(Date:10/10/2008)...omy serving as tipping point for behavior change, ...-- More than half of,Americans (51 percent) believ...are system, but major changes are needed, accordin...urvey was released today by the,Employee Benefit R...tes,Inc., and was underwritten by the Principal Fi...
Breaking Medicine News(10 mins):Health News:Little-Known Fat Can Be a Heartbreaker 2Health News:Little-Known Fat Can Be a Heartbreaker 3Health News:Healthcare Resources Available in Difficult Times 2Health News:Healthcare Resources Available in Difficult Times 3Health News:Virginia Rehabilitation Center for the Blind and Vision Impaired Celebrates Opening of New Student Dormitory 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 3
...were able to detect non progressive breast cancer ...ous studies// show that 54% of the mammograms dete...e is about 1% only. But the present study is based...a Zackrisson, a radiologist from the Epidemiologic...
...t satisfied with the relative success of the parti...eons are hungry to perform the // first full face ...c and Reconstructive Surgery? (PRS), the official ...c Surgeons (ASPS), U.S. plastic surgeons demonstra...
... of the Medical College of Wisconsin in Milwaukee ...MI) and those with the lowest BMI are at greatest ... slim increases male drivers risk of dying in a ca...ng moderately overweight might help cushion the bl...
...l Association journal is showing no signs of resol...ellow Sally Murray followed // Dr. John Hoey and A...ter a dispute over an article on the contraceptive...een asked to act as an interim editor, but the for...
Other Medicine News:Health News:Mammograms Detect Non Progressive Cancer 2
(Date:10/9/2008)... Company Prepares for Increased Sales and Marke...Progress of MitraClip(R) System, MENLO PARK, Cali...r in,the development of devices for the percutaneo...s and marketing executive team with the appointmen...wide sales and marketing and,Chris Richardson, as ...
(Date:10/8/2008)... ALEXANDRIA, Va., Oct. 8 /PRNewswire-USNewswi...ly 7,000 people die from HIV/AIDS in,sub-Saharan A...en in,sub-Saharan Africa have already died of AIDS...a is working to ensure the dying and their familie... end of life. FHSSA,s,innovative partnering initia...
(Date:10/8/2008)... Review Zanolimumab Program to be Discontinued a...ces the Results of its Portfolio Review; Zanolimum...l Reduce the Number of ...irstCall/ -- Genmab A/S (OMX: GEN),announced today...ab,(HuMax-CD4(R)). In addition, as a result of a p...
(Date:10/8/2008)... LYON, France, Oct. 8 /- Vical I...xpanded clinical data and new nonclinical data,dem...t may be broadly,applicable in DNA- and protein-ba...cancer vaccines. Alain P. Rolland, Pharm.D., Ph.D....ment, will present the data today,Wednesday, Octo...
Breaking Medicine Technology:Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Natural Remedies to Treat Animals Complex Emotions 23183 1Natural Remedies to Treat Animals Complex Emotions 23183 2New Ear Tube Device Helps Treat Infections Faster 23179 1New Ear Tube Device Helps Treat Infections Faster 23179 2Manhattan Scientifics Acquires Metallicum Inc 23176 1Manhattan Scientifics Acquires Metallicum Inc 23176 2Manhattan Scientifics Acquires Metallicum Inc 23176 3Manhattan Scientifics Acquires Metallicum Inc 23176 4Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 1Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 2Georgia to Offer More Community Living Alternatives for Individuals With Disabilities 23174 3
...ON, July 09, 2007 /PRNewswire-FirstCall/ - YM,BioS..., develops,and commercializes differentiated produ... study presented by investigators from Kinki,Unive...he 11th,meeting of The Japanese Association for Mo... 2007 demonstrated the increased,radiosensitivity ...
..., July 9 /CNW/ - Insmed Inc. (NASDAQ:INSM), a ,bio...and approval,of drugs for the treatment of metabo...nced that it will present at this,week,s C.E. Unt...s Conference in New York City. , The conference...,York City, will run from Tuesday, July 10th thro...
Other Medicine Technology:YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 2YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 3YM BioSciences Announces Preclinical Data Confirming Nimotuzumab,Binds to the EGF Receptor and Potentiates Radiotherapy 4Insmed Inc. to Present at C.E. Unterberg, Towbin Growth Conference 2
Lamellar Blade tip 6600 style, angled bevel up. Dimensions: 11.0 mm (L) x 2.4 mm (W). Cut: 3.7 mm.
19 g MVR knife. Dimensions: 31.8 mm x 1.45 mm x 3.3 mm.
Full Handle Laseredge Slit Blade Knife, 3.2 mm angled double bevel. Blade tip dimension: 14.4 mm x 3.2 mm x 4.0 mm.
Full Handle Laseredge Slit Blade Knife, 3.0 mm straight. Blade tip dimension: 14.4 mm x 3.0 mm x 3.7 mm.
Medicine Products: